Stay updated on Helix BioPharma Press Releases

Sign up to get notified when there's something new on the Helix BioPharma Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Helix BioPharma Press Releases page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    9 days ago
    No Change Detected
  3. Check
    17 days ago
    No Change Detected
  4. Check
    24 days ago
    Change Detected
    Summary
    The website has added new sections for About Us, News, and Investor, while removing the Team, Technology, and Investors sections.
    Difference
    6%
    Check dated 2025-01-12T06:49:55.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    Helix BioPharma Corp. has made significant updates, including the appointment of James B. Murphy as CFO, multiple asset purchase agreements to enhance its oncology portfolio, and the announcement of fiscal 2024 year-end results, while several older blog posts and presentations have been removed from the site.
    Difference
    100%
    Check dated 2025-01-05T00:20:47.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Summary
    Helix BioPharma Corp. has added several new presentations and abstracts from 2017 to 2023, while notable deletions include the appointment of a new CFO and multiple asset purchase agreements related to their immune-oncology portfolio.
    Difference
    100%
    Check dated 2024-12-28T21:20:14.000Z thumbnail image
  7. Check
    53 days ago
    Change Detected
    Summary
    Helix BioPharma Corp. has appointed James B. Murphy as Chief Financial Officer and amended acquisition agreements to finalize share consideration ahead of potential financing.
    Difference
    93%
    Check dated 2024-12-14T11:54:08.000Z thumbnail image
  8. Check
    60 days ago
    Change Detected
    Summary
    Helix Biopharma Corp. has entered into an asset purchase agreement to acquire an oral chemotherapy compound, marking a significant development in its portfolio, while previous announcements regarding share consolidation and executive resignations have been removed.
    Difference
    23%
    Check dated 2024-12-07T09:39:47.000Z thumbnail image
  9. Check
    67 days ago
    Change Detected
    Summary
    Helix Biopharma Corp. has entered into an asset purchase agreement to acquire an oral immune checkpoint inhibitor, expanding its immune-oncology portfolio, while the announcement regarding the grant of stock options has been removed.
    Difference
    24%
    Check dated 2024-11-30T00:16:59.000Z thumbnail image

Stay in the know with updates to Helix BioPharma Press Releases

Enter your email address, and we'll notify you when there's something new on the Helix BioPharma Press Releases page.